AYA.AX stock opens pre-market at A$3.40, up 5.59% on the ASX on 28 Feb 2026. Artrya Limited (AYA.AX) is an Australian medtech firm that sells Salix, an AI tool for coronary CT angiography. Today’s move follows a five-day gain of 5.92% and volume of 386,784 shares. We assess the AI-driven growth case, near-term financials, and technical setup for traders and investors.

Market snapshot: AYA.AX stock price and momentum

Artrya (AYA.AX) trades on the ASX in AUD at A$3.40 with a one-day change of +5.59% and intraday range A$3.20–A$3.46. Market cap stands near A$386,920,000.00 and average volume is 619,109.00 shares. The 50-day average is A$3.93 and the 200-day average is A$2.53, signalling mixed momentum. Traders should note year high A$5.24 and year low A$0.56 as reference points for volatility.

Business model and AI product: Salix adoption and sector relevance

Artrya Limited uses AI to identify coronary artery disease via the Salix cloud platform. Salix automates detection from coronary CT angiography and targets radiology providers and hospitals in Australia and overseas. The company operates in Healthcare information services, where peers trade at higher PE multiples, reflecting growth expectations. Adoption, regulatory approvals, and hospital contracts will determine revenue ramp and sector comparatives.

Financials and valuation: AYA.AX stock fundamentals

AYA.AX shows EPS of -0.17 and a trailing PE of -20.00, reflecting current losses as R&D drives growth. Cash per share is 0.61 and book value per share is 0.71, with a strong current ratio of 37.11 driven by working capital. Price to book sits at 4.53 and price to sales is elevated at 12,635.72, signalling valuation premiums versus typical healthcare peers. Revenue growth was flat in the latest fiscal year, while R&D to revenue is 84.34%, underlining a product development phase.

Technicals and trading signals for AYA.AX stock

Technical indicators are mixed: RSI 47.99, MACD histogram 0.03, and ADX 24.42 suggest a neutral trend with possible short-term consolidation. Bollinger Bands read Upper 3.66 and Lower 2.98, leaving room for a break above A$3.66 to signal momentum continuation. Average daily volume is below the 50-day average, with current volume 386,784.00, so watch liquidity spikes around news or contract announcements. Use stop-losses and size positions to manage higher volatility.

Meyka AI grade and third‑party rating for AYA.AX stock

Meyka AI rates AYA.AX with a score out of 100: 63.25 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent company rating data shows a C score with a Sell recommendation on 27 Feb 2026, reflecting weak profitability ratios. Investors should weigh Meyka’s balanced HOLD grade against the cautious third-party rating when sizing positions.

Forecasts and outlook: AYA.AX stock targets and scenarios

Meyka AI’s forecast model projects monthly A$3.09, quarterly A$5.03, and yearly A$7.83 for AYA.AX stock. A quarterly target of A$5.03 implies an upside of 47.94% from A$3.40 today, while the yearly target implies 130.16% upside. Forecasts assume steady Salix commercial adoption and manageable cash burn. Forecasts are model-based projections and not guarantees; sensitivity to contract timing and regulatory delays is high.

For a conservative view, a near-term price target range of A$3.00–A$5.00 captures possible churn and milestone-driven moves.

Final Thoughts

Key takeaways for AYA.AX stock: Artrya trades at A$3.40 on the ASX and shows mixed signals across fundamentals and technicals. The business is an AI-first medtech play with Salix positioned to scale if clinical adoption and contracting accelerate. Financials show negative EPS -0.17, elevated valuation metrics, and heavy R&D investment. Meyka AI’s forecast model projects a yearly target of A$7.83, implying 130.16% upside from A$3.40, and a quarterly target of A$5.03, implying 47.94% upside. These projections assume successful commercial rollouts and controlled cash burn. Risk factors include slower hospital uptake, reimbursement timing, and execution on international expansions. Traders seeking exposure to AI in healthcare should treat AYA.AX as a growth-speculative position, size positions for higher volatility, and monitor contract news and quarterly updates closely. Meyka AI provides this analysis as an AI-powered market analysis platform to inform research; this is not financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.